Recent Quotes (30 days)

You have no recent quotes
chg | %

InspireMD Inc  

(Public, NYSEAMERICAN:NSPR)   Watch this stock  
Find more results for NSPR
0.440
-0.006 (-1.35%)
Nov 17 - Close
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 0.42 - 0.46
52 week 0.30 - 3.99
Open 0.45
Vol / Avg. 140,137.00/622,427.00
Mkt cap 3.19M
P/E     -
Div/yield     -
EPS -1.76
Shares 7.47M
Beta 1.49
Inst. own 5%
Nov 8, 2017
Q3 2017 InspireMD Inc Earnings Call
Nov 7, 2017
Q3 2017 InspireMD Inc Earnings Release
Sep 12, 2017
InspireMD Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -290.53% -446.73%
Operating margin -290.39% -403.80%
EBITD margin - -393.72%
Return on average assets -104.46% -112.04%
Return on average equity -175.74% -1539.76%
Employees 34 -
CDP Score - -

Address

4 Menorat Hamaor St.
TEL AVIV-YAFO, MA 6744832
Israel
+1-857-4536553 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Officers and directors

Paul S. Stuka Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
James J. Barry Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Isaac Blech Independent Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Craig Shore Chief Financial Officer, Chief Administrative Officer, Treasurer and Secretary
Age: 55
Bio & Compensation  - Reuters
Agustin V. Gago Executive Vice President, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Thomas J. Kester CPA Director
Age: 69
Bio & Compensation  - Reuters
Michael Berman Independent Director
Age: 58
Bio & Compensation  - Reuters
Campbell Rogers M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters